AR092330A1 - Composiciones, metodos de absorcion transmucosa y metodo de tratamiento - Google Patents

Composiciones, metodos de absorcion transmucosa y metodo de tratamiento

Info

Publication number
AR092330A1
AR092330A1 ARP130102101A ARP130102101A AR092330A1 AR 092330 A1 AR092330 A1 AR 092330A1 AR P130102101 A ARP130102101 A AR P130102101A AR P130102101 A ARP130102101 A AR P130102101A AR 092330 A1 AR092330 A1 AR 092330A1
Authority
AR
Argentina
Prior art keywords
absorption
transmucous
compositions
methods
treatment method
Prior art date
Application number
ARP130102101A
Other languages
English (en)
Spanish (es)
Inventor
Lederman Seth
Reiner Giorgio
Brittain Harry
Original Assignee
Tonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharmaceuticals Inc filed Critical Tonix Pharmaceuticals Inc
Publication of AR092330A1 publication Critical patent/AR092330A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP130102101A 2012-06-15 2013-06-14 Composiciones, metodos de absorcion transmucosa y metodo de tratamiento AR092330A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US201361792900P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR092330A1 true AR092330A1 (es) 2015-04-15

Family

ID=49758769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102101A AR092330A1 (es) 2012-06-15 2013-06-14 Composiciones, metodos de absorcion transmucosa y metodo de tratamiento

Country Status (26)

Country Link
US (1) US20140171515A1 (OSRAM)
EP (1) EP2861223B1 (OSRAM)
JP (5) JP6259452B2 (OSRAM)
CN (2) CN104684550A (OSRAM)
AR (1) AR092330A1 (OSRAM)
AU (2) AU2013274003B2 (OSRAM)
BR (1) BR112014031394B1 (OSRAM)
CA (2) CA3118913C (OSRAM)
DK (1) DK2861223T3 (OSRAM)
ES (1) ES2929133T3 (OSRAM)
HR (1) HRP20221325T1 (OSRAM)
HU (1) HUE060175T2 (OSRAM)
IL (1) IL236268B (OSRAM)
LT (1) LT2861223T (OSRAM)
MX (2) MX382516B (OSRAM)
MY (1) MY194495A (OSRAM)
NZ (2) NZ726488A (OSRAM)
PL (1) PL2861223T3 (OSRAM)
PT (1) PT2861223T (OSRAM)
RS (1) RS63822B1 (OSRAM)
SG (2) SG11201408318RA (OSRAM)
SI (1) SI2861223T1 (OSRAM)
SM (1) SMT202200436T1 (OSRAM)
TW (3) TWI683660B (OSRAM)
WO (1) WO2013188847A1 (OSRAM)
ZA (1) ZA201500288B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171739T1 (hr) 2009-11-20 2018-03-09 Tonix Pharma Holdings Limited Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
HUE047547T2 (hu) 2013-03-15 2020-04-28 Tonix Pharma Holdings Ltd Ciklobenzaprin-hidroklorid és mannit eutektikus formulációi
SG10201902203VA (en) * 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
WO2017009472A1 (en) * 2015-07-15 2017-01-19 Theranexus Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
WO2018045367A1 (en) * 2016-09-02 2018-03-08 Nova Southeastern University Atropine sulfate rapidly-disintegrating sublingual tablets for treatment of acute organophosphate toxicity
JP2020526592A (ja) * 2017-07-13 2020-08-31 トニックス ファーマシューティカルズ ホールディング コーポレーション シクロベンザプリン類似体及びアミトリプチレン類似体
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下片及其制备方法
IL275144B2 (en) * 2017-12-08 2024-12-01 Hoffmann La Roche Pharmaceutical formulation
WO2019116091A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
SG11202101443WA (en) * 2018-08-20 2021-03-30 Tonix Pharma Holdings Ltd Methods of treating acute stress disorder and posttraumatic stress disorder
CA3156118A1 (en) * 2019-09-30 2021-04-08 Cadila Healthcare Limited Intranasal pharmaceutical compositions of cyclobenzaprine
CA3179754A1 (en) * 2020-04-08 2021-10-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
WO2022109218A1 (en) * 2020-11-20 2022-05-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
WO2022125572A1 (en) 2020-12-07 2022-06-16 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
WO2023059728A1 (en) 2021-10-06 2023-04-13 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
US20230414536A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
EP1077683B1 (en) * 1998-05-14 2002-12-11 Alza Corporation Antidepressant therapy
HK1047693A1 (zh) 1999-08-13 2003-03-07 Vela Pharmaceuticals Inc. 治疗全身性焦虑障碍的环苯扎林及其组合物
PT1202722E (pt) 1999-08-13 2005-11-30 L & L Technologies Llc Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
JP2006516963A (ja) * 2003-02-04 2006-07-13 クリサリス テクノロジーズ インコーポレイテッド エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
HRP20171739T1 (hr) * 2009-11-20 2018-03-09 Tonix Pharma Holdings Limited Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
HUE047547T2 (hu) * 2013-03-15 2020-04-28 Tonix Pharma Holdings Ltd Ciklobenzaprin-hidroklorid és mannit eutektikus formulációi

Also Published As

Publication number Publication date
SG11201408318RA (en) 2015-01-29
HK1209361A1 (en) 2016-04-01
MX2021005317A (es) 2022-12-16
PL2861223T3 (pl) 2022-12-12
HRP20221325T1 (hr) 2022-12-23
TWI590820B (zh) 2017-07-11
EP2861223A4 (en) 2016-01-27
RS63822B1 (sr) 2023-01-31
DK2861223T3 (da) 2022-11-07
TW201731494A (zh) 2017-09-16
TW201408281A (zh) 2014-03-01
CA2876902A1 (en) 2013-12-19
SG10201605407TA (en) 2016-08-30
CN111388430A (zh) 2020-07-10
JP6259452B2 (ja) 2018-01-10
TWI642429B (zh) 2018-12-01
CN104684550A (zh) 2015-06-03
BR112014031394A8 (pt) 2021-11-03
US20140171515A1 (en) 2014-06-19
JP2019123757A (ja) 2019-07-25
ZA201500288B (en) 2022-05-25
WO2013188847A1 (en) 2013-12-19
AU2013274003A1 (en) 2015-02-05
MY194495A (en) 2022-11-30
EP2861223A1 (en) 2015-04-22
IL236268B (en) 2022-03-01
WO2013188847A8 (en) 2015-02-05
JP2015519404A (ja) 2015-07-09
IL236268A0 (en) 2015-02-26
JP2021138765A (ja) 2021-09-16
AU2018241128A1 (en) 2018-10-25
SI2861223T1 (sl) 2023-01-31
MX382516B (es) 2025-03-13
NZ726488A (en) 2018-10-26
AU2013274003B2 (en) 2018-07-05
BR112014031394B1 (pt) 2022-10-18
AU2018241128B2 (en) 2020-05-21
SMT202200436T1 (it) 2023-01-13
JP2024032964A (ja) 2024-03-12
EP2861223B1 (en) 2022-08-03
TWI683660B (zh) 2020-02-01
CA3118913A1 (en) 2013-12-19
CA2876902C (en) 2021-07-13
TW201842903A (zh) 2018-12-16
ES2929133T3 (es) 2022-11-25
JP2017222726A (ja) 2017-12-21
BR112014031394A2 (pt) 2017-06-27
LT2861223T (lt) 2022-12-12
CA3118913C (en) 2024-04-30
NZ631144A (en) 2016-12-23
MX2014015436A (es) 2015-07-14
PT2861223T (pt) 2022-11-07
HUE060175T2 (hu) 2023-02-28

Similar Documents

Publication Publication Date Title
AR092330A1 (es) Composiciones, metodos de absorcion transmucosa y metodo de tratamiento
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112013018352A2 (pt) composição de minociclina tópica e método
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
UA117466C2 (uk) СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
UY34676A (es) ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?.
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
BR112015006641A2 (pt) composição farmacêutica de dose fixa, uso de uma composição farmacêutica de dose fixa, método para tratar sobrecarga crônica de ferro e processo para preparar uma composição farmacêutica de dose fixa
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014030553A2 (pt) uso cosmético, como agente para prevenir e/ou tratar um defeito estético na pele e/ou seus apêndices, método relacionado, composto, e composição dermatológica
SG11201502096VA (en) NOVEL EXTRACTS OF CYNARA SCOLYMUS, COFFEA spp. AND OLEA EUROPAEA FOR THE TREATMENT OF METABOLIC SYNDROME
CY1121749T1 (el) Προφαρμακα ανταγωνιστων nmda
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
DK3003363T3 (da) Immunogen sammensætning til anvendelse i terapi
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac
CL2015001225A1 (es) Agente terapéutico para trastornos queratoconjuntivos.
MX376175B (es) Composiciones de grapiprant y metodos para usar las mismas.

Legal Events

Date Code Title Description
FC Refusal